Frequent FDA Inspections Slow Down Indian Pharma Exports

Frequent inspections of Indian plants by the US FDA and subsequent observations slow down the growth of pharma exports even as US-China trade war presents huge opportunities for the drug industry, GV Prasad, Chairman

“It (effect of frequent inspections) is quite significant. Part of the slow Down is that. Lot of companies’ approvals have stalled because of warning letters. That has affected the new product introductions and growth,” he said.

“Everybody should up their game in terms of quality, systems, discipline, integrity of data. All there are important things for the industry,” Prasad said when asked about the effect of frequent inspections of Indian pharma manufacturing plants by the FDA and measures to be taken to reduce the impact.

Source: The Economic Times